is mounjaro a glp 1 agonists GLP-1 How is Mounjaro a GLP‑1

The secondary endpoints were the percentage change in body weight from baseline to 48 weeks and the presence of weight reduction in 5%, 10%, and 15%

Appendix Abbreviations AE(s): Adverse Event(s) BMI Body Mass Index CENTRAL Cochrane Central Register of Controlled Trials CI Confidence Interval CSF Cerebrospinal Fluid GLP-1 Glucagon-Like Peptide-1 GLP-1 RA(s) GLP-1 Receptor Agonist(s) I (Statistical measure of heterogeneity) ICP Intracranial Pressure IIH Idiopathic Intracranial Hypertension IQR Interquartile Ranges logMAR Logarithm of the Minimum Angle of Resolution MD Mean Difference NOS Newcastle-Ottawa Quality Assessment Scale PICO Population, Intervention, Comparison, and Outcomes PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses PROSPERO (International prospective register of systematic reviews Name, not an acronym defined in text) RCT(s) Randomized Controlled Trial(s) RoB2 Revised Cochrane risk-of-bias tool (for randomized trials) RR Risk Ratio SD Standard Deviation SMD Standardized Mean Difference ULN Upper Limit of Normal VRS Verbal Rating Scale WOS/WoS Web of Science Footnotes ORCID iDs: Jamal Ahmad Ahmed Mohamed Hamdy Bahaa Elfakharany Muhammad M

Different medications have different adaptation timelines

Survival rates after myocardial infarction also improved after GLP-1 administration

U.Ss Food and Drug Administration

A new wave of GLP-1 medications looms over the horizon